<DOC>
	<DOCNO>NCT03027128</DOCNO>
	<brief_summary>The purpose study determine whether haNK™ Infusion safe effective treatment metastatic locally advanced solid tumor .</brief_summary>
	<brief_title>QUILT-3.028 : Study haNK™ Infusion Subjects With Metastatic Locally Advanced Solid Tumors</brief_title>
	<detailed_description>This phase 1 trial subject metastatic locally advanced solid tumor . The study conduct two part : part 1 involve dose escalation use 3 + 3 design , part 2 involve expansion MTD HTD evaluate safety haNK . In part 1 , 3 6 subject sequentially enrol start dose cohort 1 , subject assess DLTs . - Cohort 1 : 2 x 10^9 cell per infusion . - Cohort 2 : 4 x 10^9 cell per infusion . - If need , subject enrol dose de-escalation cohort ( cohort -1 ) : 1 x 10^9 cell per infusion . In part 2 , dose expansion occur MTD HTD determine . An additional 4 subject may enrol part 2 , total 10 subject MTD HTD .</detailed_description>
	<criteria>1 . Age ≥ 18 year old . 2 . Able understand provide sign informed consent fulfills relevant IRB IEC guideline . 3 . Histologically confirm , unresectable , locally advanced metastatic solid malignancy . 4 . ECOG performance status 0 2 . 5 . Have least 1 measurable lesion and/or nonmeasurable disease evaluable accord RECIST Version 1.1 . 6 . Must historic FFPE tumor biopsy specimen ≤ 6 month old willing release specimen tumor molecular profiling analysis . If historic specimen available take &gt; 6 month date screening , subject must willing undergo biopsy screen period . 7 . Must willing provide pre postinfusion blood sample exploratory analysis . 8 . Have receive treatment least 1 prior line therapy metastatic set candidate therapy proven efficacy disease . Prior immune therapy allow . 9 . Resolution toxic side effect prior chemotherapy , radiotherapy , surgical procedure CTCAE grade ≤ 1 , exception alopecia . 10 . Life expectancy ≥ 12 week . 11 . Ability attend require study visit return adequate follow , require protocol . 12 . Agreement practice effective contraception ( male female subject , risk conception exists ) . Because effect haNK cell develop human fetus unknown , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation , 30 day last dose haNK™ Infusion . If employing contraception , two follow precaution must use : vasectomy partner , tubal ligation , vaginal diaphragm , intrauterine device , condom spermicidal ( gel/foam/cream/vaginal suppository ) , total abstinence . Male subject must surgically sterile must agree use condom acceptable contraceptive method partner . Female subject postmenopausal define absence menses &gt; 12 consecutive month . 1 . History persistent grade 2 high ( CTCAE Version 4.03 ) hematological toxicity result previous therapy . 2 . Evidence central nervous system disease 3 . History active malignancy brain metastasis except : control basal cell carcinoma squamous cell carcinoma ; prior history situ cancer ( eg , breast , melanoma , squamous cell carcinoma skin , cervical ) &gt; 5 year without evidence disease ; prior history prostate cancer active systemic treatment ( except hormonal therapy ) undetectable PSA ( &lt; 0.2 ng/mL ) . 4 . Serious uncontrolled concomitant disease would contraindicate use investigational drug use study would put subject high risk treatmentrelated complication . 5 . Systemic autoimmune disease ( eg , lupus erythematosus , rheumatoid arthritis , Addison 's disease , autoimmune disease associate lymphoma ) . 6 . History organ transplant require immunosuppression . 7 . History active inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) . 8 . Inadequate organ function , evidence follow laboratory result : WBC count &lt; 3,500 cells/mm3 Absolute neutrophil count &lt; 1,500 cells/mm3 Platelet count &lt; 100,000 cells/mm3 Hemoglobin &lt; 9 g/dL Total bilirubin great ULN ( unless subject document Gilbert 's syndrome ) Aspartate aminotransferase ( AST [ SGOT ] ) alanine aminotransferase ( ALT [ SGPT ] ) &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver metastasis ) Alkaline phosphatase level &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver metastasis , &gt; 10 × ULN subject bone metastasis ) Serum creatinine &gt; 2.0 mg/dL 177 μmol/L INR aPTT PTT &gt; 1.5 × ULN ( unless therapeutic anticoagulation ) 9 . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( ie , active ) cardiovascular disease , cerebrovascular accident/stroke , myocardial infarction within 6 month prior first study medication ; unstable angina ; congestive heart failure New York Heart Association grade 2 high ; serious cardiac arrhythmia require medication . 10 . Dyspnea rest due complication advance malignancy disease require continuous oxygen therapy . 11 . Positive result screen test HIV , HBV , HCV infection . 12 . Current chronic daily treatment ( continuous &gt; 3 month ) systemic corticosteroid ( dose equivalent great 10 mg/day methylprednisolone ) , exclude inhaled steroid . Shortterm steroid use prevent IV contrast allergic reaction anaphylaxis subject know contrast allergy allow . 13 . Known hypersensitivity component study medication ( ) . 14 . Participation investigational drug study history receive investigational treatment within 28 day prior screen study , except testosteronelowering therapy men prostate cancer . 15 . Assessed investigator unable unwilling comply requirement protocol . 16 . Concurrent participation interventional clinical trial . 17 . Pregnant nursing woman . A negative serum pregnancy test within 72 hour administration haNK™ Infusion must document haNK™ Infusion administer woman childbearing potential ( WOCBP ) . WOCBP consider woman physiologically capable become pregnant . WOCBP usually premenopausal woman woman le 12 month amenorrhea postmenopause undergone surgical sterilization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cell Therapy</keyword>
</DOC>